MTOR and breast carcinoma: A previous study showed that dual inhibition of PI3K/mTOR in BEZ235-resistant breast cancer cells triggered a positive feedback response and activated the JAK2/STAT5 pathway, resulting in increased IL-8 secretion and drug resistance32.